macrogol 3350, sodium hydrogen carbonate,
sodium chloride, potassium chloride
is significantly more
effective than lactulose
Liquid Orange Flavour, concentrate for oral solution.
Abbreviated Prescribing Information
REFER TO FULL SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) BEFORE PRESCRIBING.
MOVICOL Sachet of white powder which dissolves in about 125ml (approximately
½ glassful) water to make a lemon/lime flavoured drink. Each sachet contains: 13.125g macrogol
(polyethylene glycol) 3350, 178.5mg sodium hydrogen carbonate, 350.7mg sodium chloride and
46.6mg potassium chloride. MOVICOL Liquid A clear concentrated liquid, which is diluted in water to
make an orange flavoured drink. Each 25 ml of MOVICOL Liquid is diluted in 100 ml of water before
use and contains the following active ingredients: 13.125 g macrogol (polyethylene glycol) 3350,
178.5 mg sodium hydrogen carbonate, 350.7 mg sodium chloride and 46.6mg potassium chloride.
Treatment of chronic constipation.
Dosage and administration:
adolescents and the elderly: 1-3 sachets daily in divided doses, according to individual response. For
extended use: adjust dose down to 1 or 2 sachets. Extended use may be necessary in patients with
severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson’s Disease, or
induced by regular constipating medicine, in particular opioids and antimuscarinics. A course of
MOVICOL treatment does not normally exceed 2 weeks, but can be repeated if required.MOVICOL
Liquid Adults, adolescents and the elderly: 25 ml diluted in 100 ml of water 1-3 times daily in divided
doses, according to individual response. For extended use, the dose can be adjusted down to 1 or 2
doses per day, each consisting of 25 ml diluted in 100 ml of water. Extended use may be necessary in
patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson’s
Disease, or induced by regular constipating medicine, in particular opioids and antimuscarinics. A
course of MOVICOL Liquid treatment does not normally exceed 2 weeks, but can be repeated if
required.MOVICOL and MOVICOL Liquid are not recommended for children below 12 years.
Alternative MOVICOL products are available for children.
perforation or obstruction due to structural or functional disorders of the gut wall, ileus, severe
inflammatory conditions of the intestinal tract, such as Crohn’s disease, ulcerative colitis and toxic
megacolon. Hypersensitivity to the active substances or any of the excipients.
precautions for use:
If patients develop any symptoms indicating shifts of fluids/electrolytes
treatment should be stopped immediately. MOVICOL Liquid contains 8.125 mmol of sodium in each
diluted dose of 125 ml and should be considered when administered to patients on a controlled
sodium diet. MOVICOL Liquid contains benzyl alcohol. Do not exceed the maximum recommended
There is a possibility that the absorption of concomitantly administered
medication could be transiently reduced.
Pregnancy and lactation:
Can be used during pregnancy
Reactions related to the gastrointestinal tract are the most
common and include: abdominal pain, abdominal distension, nausea, dyspepsia, vomiting, diarrhoea,
flatulence, borborygmi and anal discomfort. Allergic reactions, including anaphylactic reaction,
angioedema, dyspnoea and skin reactions can occur. Other effects can include electrolyte disturbances,
headache and peripheral oedema.
UK P, IE Prescription- only.
sachets £4.45, IE €6.55, 30 sachets £6.68, IE € 9.83, 50 sachets £11.13, IE Not available. MOVICOL
Liquid Cost: 500ml UK £4.45, IE €7.71.
MOVICOL: UK PL 00322/0070, IE PA
0102/023/002. MOVICOL Liquid: UK PL20011/0007, IE PA 1336/2/4.
For further information
Norgine Pharmaceuticals Limited, Norgine House, Moorhall Road, Harefield, Middlesex, UB9
6NS. Telephone: +44 (0) 1895 826606. E-mail:
is a registered
trademark of the NORGINE
group of companies.
Date of preparation/revision:
Adverse events should be reported. Reporting forms and information can be found
Adverse events should also be reported to
Medical Information at Norgine Pharmaceuticals Ltd on +44 (0) 1895 826606.
Adverse events should be reported to Medical Information at
Norgine Pharmaceuticals on +44 1895 826606.
Date of preparation:
Now can be used in